Part 2/11:
As of 2024, it is estimated that up to one in eight Americans are using GLP-1 receptor agonists such as Ozempic, Wegovy, or Regeron. These injectable drugs, originally developed for managing type 2 diabetes, have gained notoriety for their remarkable effectiveness in producing rapid weight loss. Hollywood celebrities and high-profile individuals are openly sharing their use, further fueling demand. It’s become less about lifestyle changes and more about pharmacological intervention.
This shift has caused a cascade of consequences, including the decline of traditional diet clubs. But more concerning is what experts are now warning about: new, disturbing side effects associated with prolonged use of these drugs.